INAB
In8bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$15.46M
P/E Ratio
—
EPS
$-2.54
Beta
0.08
52W High
$5.61
52W Low
$1.17
50-Day MA
$1.56
200-Day MA
$1.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About In8bio Inc
IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-17.84M |
| Operating Margin | 0.00% |
| Return on Equity | -103.60% |
| Return on Assets | -52.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.31 |
| Price-to-Book | 0.68 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $9.85M |
| Float | $7.03M |
| % Insiders | 20.79% |
| % Institutions | 38.12% |
Historical Volatility
HV 10-Day
72.32%
HV 20-Day
60.52%
HV 30-Day
57.41%
HV 60-Day
81.81%
HV Rank
14.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.25 target)
1
Strong Buy3
BuyMore HEALTHCARE Stocks
Data last updated: 5/23/2026